Nyrada Inc (NYR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nyrada Inc (NYR) has a cash flow conversion efficiency ratio of -0.453x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-4.46 Million ≈ $-3.16 Million USD) by net assets (AU$9.84 Million ≈ $6.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Nyrada Inc (NYR) market capitalisation for the company's overall valuation and market capitalisation.
Nyrada Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Nyrada Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nyrada Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nyrada Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Nyrada Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dmc Global Inc
NASDAQ:BOOM
|
-0.034x |
|
BINEX Co. Ltd
KQ:053030
|
0.019x |
|
Eagle Cold Storage Enterprise Co Ltd
TWO:8905
|
0.038x |
|
Strickland Metals Ltd
AU:STK
|
-0.004x |
|
Avita Medical Ltd
NASDAQ:RCEL
|
0.327x |
|
Moens Bank A/S
CO:MNBA
|
N/A |
|
Whanin Pharm
KO:016580
|
0.022x |
|
Corpovael S.A.B. de C.V
MX:CADUA
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Nyrada Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nyrada Inc from 2018 to 2025. View latest Nyrada Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$3.58 Million ≈ $2.53 Million |
AU$-5.05 Million ≈ $-3.57 Million |
-1.412x | -831.05% |
| 2024-06-30 | AU$5.05 Million ≈ $3.57 Million |
AU$-766.29K ≈ $-542.20K |
-0.152x | +91.07% |
| 2023-06-30 | AU$4.26 Million ≈ $3.01 Million |
AU$-7.23 Million ≈ $-5.12 Million |
-1.698x | -565.58% |
| 2022-06-30 | AU$11.50 Million ≈ $8.14 Million |
AU$-2.93 Million ≈ $-2.08 Million |
-0.255x | -33.34% |
| 2021-06-30 | AU$14.49 Million ≈ $10.25 Million |
AU$-2.77 Million ≈ $-1.96 Million |
-0.191x | +76.02% |
| 2020-06-30 | AU$5.53 Million ≈ $3.91 Million |
AU$-4.41 Million ≈ $-3.12 Million |
-0.798x | -297.19% |
| 2019-06-30 | AU$-4.95 Million ≈ $-3.51 Million |
AU$-2.01 Million ≈ $-1.42 Million |
0.405x | -20.09% |
| 2018-06-30 | AU$-1.36 Million ≈ $-964.18K |
AU$-690.18K ≈ $-488.35K |
0.506x | -- |
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more